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In the continuing search for effective cancer treatments, we report the rational engineering of a multifunctional nanoparticle
that combines traditional chemotherapy with cell targeting and anti-adhesion functionalities. Very late antigen-4 (VLA-4)
mediated adhesion of multiple myeloma (MM) cells to bone marrow stroma confers MM cells with cell-adhesion-mediated
drug resistance (CAM-DR). In our design, we used micellar nanoparticles as dynamic self-assembling scaffolds to present
VLA-4-antagonist peptides and doxorubicin (Dox) conjugates, simultaneously, to selectively target MM cells and to overcome
CAM-DR. Dox was conjugated to the nanoparticles through an acid-sensitive hydrazone bond. VLA-4-antagonist peptides were
conjugated via a multifaceted synthetic procedure for generating precisely controlled number of targeting functionalities.
The nanoparticles were efﬁciently internalized by MM cells and induced cytotoxicity. Mechanistic studies revealed that
nanoparticles induced DNA double-strand breaks and apoptosis in MM cells. Importantly, multifunctional nanoparticles
overcame CAM-DR, and were more efﬁcacious than Dox when MM cells were cultured on ﬁbronectin-coated plates. Finally,
in a MM xenograft model, nanoparticles preferentially homed to MM tumors with B10 fold more drug accumulation and
demonstrated dramatic tumor growth inhibition with a reduced overall systemic toxicity. Altogether, we demonstrate the
disease driven engineering of a nanoparticle-based drug delivery system, enabling the model of an integrative approach
in the treatment of MM.
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INTRODUCTION
Multiple myeloma (MM) is a B-cell malignancy characterized by
proliferation of monoclonal plasma cells in the bone marrow (BM).
Despite the recent advances in treatment strategies and the
emergence of novel therapies, it still remains incurable with a
median survival of 3--5 years owing to development of drug
resistance.
1,2 A major factor that leads to drug resistance in MM
patients is the survival advantages provided by the BM micro-
environment. It is well demonstrated that adhesion of MM cells to
the BM stroma results in cell-adhesion-mediated drug resistance
(CAM-DR), and that the MM cells in the BM microenvironment are
much less sensitive to chemotherapeutic agents.
3,4 Anti-adhesion
therapy is evolving as a promising approach in oncology,
particularly in MM.
5 Therefore, therapeutic agents that have
the combined effect of targeting MM cells and inhibiting
their adhesion to BM milieu would provide an advantage by
overcoming CAM-DR for improved patient outcome.
Very late antigen-4 (VLA-4; also known as a4b1 integrin) is a cell
surface heterodimer expressed on cancers of hematopoietic
origin, such as lymphomas, leukemias and MM.
4,6--8 In MM,
VLA-4 is a key adhesion molecule that acts as a receptor for the
extracellular matrix protein ﬁbronectin, and the cellular counter-
receptor VCAM-1.
2 Studies demonstrated that VLA-4 has a critical
role in CAM-DR of MM cells and provides resistance to ﬁrst line
chemotherapeutics such as doxorubicin (Dox).
4,9 Importantly,
inhibition of MM cell adhesion to the BM microenvironment
via a4-integrin blocking antibodies or a4-siRNA overcomes drug
resistance in MM cells.
9- -11Combined, these results suggest VLA-4
as an attractive therapeutic target, both for selective targeting of
MM cells, as well as for inhibition of CAM-DR.
Nanotechnology has been recognized by the National Cancer
Institute as a paradigm changing opportunity with the potential to
make signiﬁcant breakthroughs in cancer diagnosis and therapy.
12
One of the most important premises of nanotechnology-based
drug delivery systems is the enhanced accumulation in tumor
tissue due to the leaky vasculature found in the angiogenic vessels
seen predominantly in solid tumors.
13,14 Recent evidence in
research has established that angiogenesis also has a major role in
some hematological malignancies including MM.
15--17 In line
with these ﬁndings, liposomal Dox has shown beneﬁcial clinical
outcome in MM patients in various settings, and has recently been
FDA approved in combination with bortezomib in the treatment
of relapsed or refractory MM.
18--20 Despite the recent advances in
nanoparticle-based therapeutics in MM, the advantages nanome-
dicine can provide have yet to be harnessed to their full potential
in treating MM.
PEGylated micellar nanoparticles have recently gained
increased popularity as efﬁcient drug delivery systems as they
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size range of 10--100nm for increased tumor accumulation and
decreased systemic toxicity.
21 An important feature of micellar
nanoparticles is that they present particularly attractive scaffolds
for the multivalent display of multiple functional groups on their
surfaces.
22
Here, we report the rational engineering of a multifunctional
nanoparticle that combines traditional chemotherapy with cell
targeting and anti-adhesion functionalities for targeted delivery of
Dox to MM cells while overcoming CAM-DR. This is accomplished
by designing particles that are simultaneously functionalized
with controlled numbers of a VLA-4-antagonist peptide and
pH-sensitive Dox conjugates. When the nanoparticles are
delivered, they target VLA-4 expressing MM cells, inhibit cellular
adhesion via VLA-4, and overcome CAM-DR. At the same time,
nanoparticle binding to VLA-4 triggers receptor-mediated uptake,
which results in active Dox release due to pH-sensitive bond
hydrolysis in the acidic endocytic vesicles. Taken together, we
demonstrate the disease-driven engineering of a nanoparticle-
based drug delivery system, enabling the model of an integrative
approach in the treatment of MM.
MATERIALS AND METHODS
Synthesis of peptide- and Dox-conjugated lipids and nanoparticles
Peptides, and peptide/DSPE-PEG2000 lipid conjugates, were synthesized
on Wang resin using Fmoc chemistry (peptide synthesis chemicals/
reagents from NovaBiochem, Philadelphia, PA, USA; DSPE-PEG2000 from
Avanti Lipids, Alabastar, AL, USA). Resin cleavage of all peptide products
was done with TFA, puriﬁcation via RP-HPLC and characterization by
MALDI-TOF-MS. Peptide cyclization through disulﬁde bond formation was
performed in 3ml DMF with 20ml DIEA by stirring for 8h at room
temperature. For Dox conjugation, DPPE-GA, hydrazine and diisopropyl-
carbodiimide were mixed in a vial and allowed to react for 4h at room
temperature. Solvent and excess reactants were removed via evaporation
under vacuum. Product was re-dissolved in chloroform, mixed with Dox in
methanol and coupled over 3 days. Final product was isolated via
extraction, and characterized with MALDI-TOF-MS. For nanoparticle
formation, nonfunctionalized and functionalized lipids were mixed at
desired molar ratios in DCM, followed by solvent removal via evaporation.
The mixture was then re-suspended in PBS, and stirred until clear.
Particle size characterization
Dynamic light-scattering analysis was performed via the 90Plus Nanopar-
ticle Analyzer (Brookhaven Instruments, Holtsville, NY, USA) using 658nm
light, at a ﬁxed angle of 901 at 201C. Samples were centrifuged for 30min
before analysis to eliminate dust and larger aggregates.
Dox release kinetics
Dox-conjugated nanoparticles ([Dox]¼34.5mM) were prepared and release
rates were analyzed at pH¼7.4, pH¼5.5 and 0.24 N HCl. Amount of free
Dox at different time points were quantiﬁed using a Toyopearl AF-Amino-
650M resin (Tosoh, Tokyo, Japan) packed column on Agilent series 1200
HPLC (Agilent, Santa Clara, CA, USA) at 477nm. All data were normalized to
total Dox released in HCl solution where hydrolysis was 100% within
B5min.
Cell culture
All cell lines were obtained from ATCC (Manassas, VA, USA), and were
cultured as previously described.
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Flow cytometry
a4- and b1-integrin subunits were detected using anti-CD49d (PE) or anti-
CD29 (FITC) antibodies (BD Biosciences, San Jose, CA, USA). Isotype
matched antibodies were used as negative controls. Apoptotic cells were
detected with Annexin-V (FITC) antibody (BD Pharmingen, San Diego,
CA, USA). Cells were analyzed with Guava EasyCyte ﬂow cytometer
(Millipore, Billerica, MA, USA).
Cell-binding assay
MM cells were incubated on ice, for 1h, with FITC-labeled peptides in
binding buffer (25mM Tris, 150mM NaCl, 1.5mM MgCl2, 1.5mM MnCl2,5m M
glucose, 1.5mM BSA). Cells were washed twice and analyzed with Guava
EasyCyte ﬂow cytometer. FITC-labeled scrambled peptide was used as
nonspeciﬁc control, and was subtracted from each data point.
Adhesion assay
The Vybrant Cell Adhesion Assay Kit (Molecular Probes, Grand Island, NY,
USA) was used according to the manufacter’s instructions. Brieﬂy, calcein-
labeled MM cells were added to ﬁbronectin-coated 96-well plates
(40mg/ml) in adhesion buffer (RPMI-1640/ 2% FBS) for 2h. To evaluate
the adhesion inhibitory effects of the VLA-4 antagonist peptides, or
peptide functionalized nanoparticles, calcein-labeled cells were added to
ﬁbronectin-coated plates and immediately treated with the inhibitory
agents. Nonadherent cells were removed by washing with PBS. Adherent
cells were quantitated in a ﬂuorescence multi-well plate reader.
Cellular uptake studies
Cells were incubated at 371C with rhodamine-labeled nanoparticles in
complete media for the indicated time points, and were analyzed with ﬂow
cytometer. For confocal microscopy experiments, cytospinned cells were
ﬁxed with 4% paraformaldehyde and mounted with VectaShield antifade/
DAPI (Vector Labs, Burlingame, CA, USA). Cells were visualized by Nikon
A1R confocal microscope with a  40 oil lens (Nikon Instruments, Melville,
NY, USA). Image acquisition was performed by Nikon Elements Ar software
(Nikon).
Cytotoxicity assays
CCK-8 (Dojindo, Rockville, MD, USA) was used as previously described.
9 To
determine cytotoxicity in the presence of ﬁbronectin, MM cells were plated
on ﬁbronectin coated plates (40mg/ml), in adhesion buffer, for 1h. Cells
were then treated with nanoparticles or free Dox in complete media with
10% FBS, for 72h. BSA coated plates were used as controls.
Western blotting
Western blotting of MM cells was performed as described before.
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Immunocytochemistry
Cytospin of drug--treated cells were prepared on slides, and ﬁxed with
4% paraformaldehyde. Slides were stained with g-H2AX antibody
(Cell Signaling, Danvers, MA, USA) and with Alexa Fluor-488-labeled Fab2
(Molecular Probes) as per manufacturer’s instructions. Mounted slides
(VectaShield antifade/DAPI) were analyzed by Nikon Eclipse TS100
ﬂuorescence microscope at  60/0.5--1.25 oil, with a Nikon Inﬁnity
camera (Nikon).
MM xenograft mouse model
CB.17 SCID mice (Harlan Laboratories, Indianapolis, IN, USA) were irradiated
with 150 rad, and inoculated subcutaneously with 5 10
6 NCI-H929 cells.
When tumors were palpable, mice were distributed into four groups of
6--8 mice, and were treated intravenously with NPDox/VLA4 pep,N P Dox, free
Dox, or vehicle (PBS), on days 1, 3 and 5. Animals were monitored for body
weight and tumor volume. In a separate experiment, three tumor
challenged mice from each group were killed on day 5 to determine
systemic toxicity. Organ weights were measured. For complete blood
count analysis, 200ml of blood was drawn from each mouse via cardiac
puncture, immediately mixed with 50ml of Sequester Solution (Cambridge
Diagnostic Products, Fort Lauderdale, FL, USA), and was analyzed with the
HemaVet 950 (Drew Scientiﬁc, Dallas, TX, USA). Immunohistochemical
staining of excised tumors for caspase-3 was performed as formerly
described.
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Mice were dissected 24h after injection with 10mg/kg free Dox or
Dox equivalent nanoparticles. Tissues were processed as previously
described,
25 and were analyzed for Dox ﬂuorescence (ex. 490nm/em.
550nm).
Statistical analysis
Statistical comparisons of continuous variables were carried out by
Student’s two-tailed t-test.
RESULTS
Identiﬁcation of a VLA-4 antagonist peptide that selectively binds
to MM cells and inhibits MM cell adhesion to ﬁbronectin
It is well established that MM cells express VLA-4 receptor, and
that VLA-4 facilitates CAM-DR in MM cells.
4,9 We, therefore,
validated VLA-4 expression in several MM cell lines, by detecting
a4- and b1-integrin subunits expression, using ﬂow cytometry
(Figure 1a). Several VLA-4-targeting peptides were identiﬁed
because of the critical role VLA-4 has in cancers.
26--28 None of
these peptides, however, have been tested for their speciﬁc
binding to MM cells, or their adhesion inhibitory effects. Both of
these criteria are crucial in our targeting strategy; we therefore
generated and screened a small library of peptides from literature.
For cellular binding assays, we synthesized FITC-labeled version of
the peptides and compared their afﬁnity to MM cells by ﬂow
cytometry. We established that the cyclic peptide Tyr-Cys-Asp-Pro-
Cys (VLA4-pep; Figure 1b) binds to MM cells with speciﬁcity
(Figure 1c). Control experiments performed with FITC-labeled
nonspeciﬁc peptide showed only minimal background binding
and was subtracted from each data point. Competitive-binding
experiment performed with excess unlabeled VLA4-pep showed
inhibition of ﬂuorescence signal indicating that VLA4-pep
speciﬁcally binds to VLA-4 receptor on MM cells (results not
shown). VLA4-pep also proved to be a potent inhibitor of MM cell
adhesion to ﬁbronectin in a typical calcein-based cell adhesion
assay (Figure 1d). Control experiments done with nonspeciﬁc
peptide did not show any adhesion inhibitory effects (results
not shown). Taken together, VLA4-pep prevailed as the leading
VLA-4 antagonist peptide and was incorporated as the targeting
and anti-adhesion moiety in the nanoparticles.
Synthesis of VLA-4 targeting, Dox-conjugated multifunctional
micellar nanoparticles
The nanoparticles were synthesized from the lipid-PEG block
co-polymer, DSPE-PEG2000. This PEG-lipid, when placed in water,
is reported to self-assemble and form micelles.
29--31 Their size
exploits the enhanced permeation and retention (EPR) effect and
prevents their entry through healthy endothelium pores.
32,33
Meanwhile, PEG conjugation increases the micelle’s solubility,
biocompatibility, provides stealth against the reticuloendothelial
system (RES) and improves circulation time.
29 DSPE-PEG2000
lipid has a low critical micellar concentration (CMC) of 5--10mM,
allowing for experimentation at therapeutically relevant
concentrations without lipid dissociation.
29,31 DSPE-PEG2000 lipid
also has a terminal primary amine version allowing for facile
conjugation of various molecular moieties.
For incorporation of VLA4-pep into the nanoparticles, VLA4-
pep/DSPE-PEG2000 conjugates were synthesized using a synthetic
strategy that was developed in our group using solid support
methodology as outlined in Figure 2a. VLA4-pep was ﬁrst
synthesized on a Wang resin using Fmoc protocols, followed by
the reaction of succinic anhydride at the N-terminal amine to
generate a carboxylic acid group at the terminus. This
newly generated carboxylic acid group on the resin bound
peptide was activated, and DSPE-PEG2000-NH2 lipid was
introduced in anhydrous DMF to promote amide coupling.
The peptide-PEG-lipid conjugate was cleaved from the resin using
a TFA cocktail, puriﬁed via HPLC and characterized by MALDI-TOF-
MS. Dox/DPPE-GA lipid conjugation was accomplished using a pH-
sensitive hydrazone chemistry to provide controlled drug release
(Figure 2b).
34 Hydrazine was ﬁrst coupled to the carboxylic head
group of the lipid, followed by the conjugation of Dox. The
conjugate was puriﬁed via extraction into chloroform.
Multifunctional micelles were prepared by mixing
DSPE-PEG2000, VLA4-pep/DSPE-PEG2000 conjugate and Dox/
DPPE-GA conjugate at desired molar ratios (Figure 2c). Each
micelle comprises B90 lipid molecules,
29,35 and their relative
monodispersity allows for incorporation of precise numbers of
functionalized lipids per particle to provide control over the
valency of the targeting peptide and drug loading. Dynamic light-
scattering analysis established that regardless of the number and
type of functional moieties included, the particles maintained their
original size of B20nm (Figure 2d).
Dox was conjugated to the lipids via an acid labile bond to
prevent the premature release of the chemotherapeutic and thus
Figure 1. VLA-4 antagonist peptide binds to MM cells, and inhibits
their adhesion to ﬁbronectin. (a) MM.1S, NCI-H929, U266 and IM9
cell lines all express VLA-4 subunits a4- and b1-integrins as de-
termined by ﬂow cytometry. Black columns are primary antibodies
and gray columns are isotype controls. (b) Structure of VLA-4
antagonist peptide (VLA4-pep). (c) Cellular-binding assays were
performed using FITC-labeled VLA4-pep and was detected by
ﬂow cytometry. Control experiments were done with FITC-labeled
nonspeciﬁc peptide and the background binding was subtracted for
each data point. VLA4-pep binds to U266, NCI-H929 and IM9 cell
lines with apparent Kd of B250nM.( d) VLA4-pep inhibits adhesion
of MM cell lines to ﬁbronectin-coated plates. BSA-coated plates were
used as controls, and no adhesion of MM cells was observed.
No inhibition of adhesion was observed in the control experiments
done with nonspeciﬁc peptide (results not shown). All experiments
were done in triplicates and data represents means (±s.d.).
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environment of endosomes catalyzes the release of active Dox,
providing localized delivery inside the tumor cells. The drug
release proﬁles we observed in pH 7.4 and pH 5.5 established that
Dox is released from the nanoparticles preferentially under acidic
conditions (Figure 2e).
Besides multifunctional nanoparticles with Dox and VLA4-pep
conjugates (NPDox/VLA4 pep), other nanoparticles synthesized
for control experiments include only Dox conjugated (NPDox),
only VLA4-pep conjugated (NPVLA4 pep), Dox and nonspeciﬁc
peptide conjugated (NPDox/ns), nonspeciﬁc-peptide conjugated
(NPns) and bare nanoparticles (NPbare). For imaging and cellular
uptake experiments, lissamine rhodamine PE was incorporated in
the micelles during formation. In all experiments, the total lipid
concentration was above the CMC.
Cellular uptake studies of VLA-4-targeting nanoparticles
Next, we evaluated if VLA4-pep functionalized nanoparticles
were taken up by MM cells and determined the optimal peptide
valency per micelle for most efﬁcient uptake. Cellular uptake
of rhodamine-labeled nanoparticles with varying number of
VLA4-pep conjugates (n¼0--40/nanoparticle) was studied via
ﬂow cytometry. Nanoparticle uptake by NCI-H929 cells increased
with increasing VLA4-pep valency up to n¼20, then dropped
dramatically at n¼40 (Figure 3a). Speciﬁcally, we observed that
20 peptides per particle yielded the maximum uptake, with up to
10-fold enhancement over that of nontargeted micelles (n¼0)
after 24h. We also used NPns (n¼20) as a control, and have
observed similar results to that of NPbare (Figure 3b). To establish
that uptake of VLA4-pep-conjugated particles were receptor
mediated, we performed competition experiments, where MM
cells were co-incubated with NPVLA4 pep (n¼20) and excess free
VLA4-pep. The results showed a dramatic reduction in cellular
uptake back to the levels of NPbare, proving receptor involvement
in uptake (Figure 3b). It is noteworthy that we observed some
nanoparticle uptake even with non-targeted micelles indicating
low levels of nonreceptor-mediated uptake (Figures 3a and b).
The studies described above were performed using ﬂow
cytometric analysis, as it is a highly accurate quantitative method
for studying the effect of peptide valency on uptake. One
shortcoming of this method, however, is that it does not
discriminate surface bound nanoparticles from internalized ones.
Therefore, to show that the nanoparticles are indeed internalized
by MM cells, we performed confocal microscopy experiments.
These experiments revealed clear uptake of VLA4-pep-conjugated
Figure 2. Synthesis and characterization of VLA-4 targeting, Dox-conjugated multifunctional nanoparticles (NPDox/VLA4 pep). (a) Schematic
illustration of the multifaceted synthetic steps for peptide conjugation to DSPE-PEG2000-NH2 using solid support. (b) Schematic illustration of
Dox conjugation to DPPE-GA. (c) Illustration of multifunctional micellar nanoparticles that incorporate VLA4-pep and Dox. (d) Dynamic light-
scattering analysis of nanoparticles. VLA-4 targeting, Dox conjugated (NPDox/VLA4 pep), only Dox conjugated (NPDox), only VLA4-pep con-
jugated (NPVLA4 pep), Dox and nonspeciﬁc peptide conjugated (NPDox/ns), nonspeciﬁc-peptide conjugated (NPns) and bare nanoparticles
(NPbare) all gave an average size distribution of B20nm. (e) Drug release proﬁle of Dox from the nanoparticles in pH¼5.5 and pH¼7.4. Rate
of hydrolysis was quantiﬁed via HPLC, taking measurements at pre-determined time intervals and observing the absorbance at wavelength of
477nm. Data shown are from a representative experiment.
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Altogether, these studies showed efﬁcient receptor-mediated
uptake of nanoparticles with optimal uptake properties of n¼20
VLA4-pep per micelle. Therefore a valency of 20 peptides per
particle was used for rest of our studies.
Multifunctional nanoparticles are cytotoxic against MM cells
We evaluated the cytotoxicity of NPDox/VLA4 pep against
NCI-H929 MM cells using a colorimetric assay. NPDox/VLA4 pep was
signiﬁcantly cytotoxic to MM cells with IC50 values of 0.39±0.06
and 0.13±0.02mM, at 48 and 72h, respectively (Figure 4). Control
experiments performed with equivalent doses of free Dox
showed a moderate advantage over NPDox/VLA4 pep at 48h
(IC50¼0.19±0.04mM). This difference was diminished at 72h,
and both free Dox and NPDox/VLA4 pep showed similar cytotoxic
effects (IC50B0.13mM). The difference in cytotoxicity at 48h is
expected given the differences in the cellular uptake mechanisms
of free Dox and NPDox/VLA4 pep. While free Dox is taken up via
passive diffusion and is active immediately, we designed our
nanoparticles to release active Dox only after they are internalized
and are exposed to the acidic environment of the endocytic
vesicles. Control experiments done with NPDox showed much
reduced cytotoxic effects at 48 and 72h, further conﬁrming
VLA-4’s role in nanoparticle uptake (Figure 4). Control experiments
performed with NPDox/ns yielded very similar results to those
obtained with non-targeted NPDox (results not shown). No
cytotoxic effects were observed in additional control experiments
performed with nanoparticles lacking Dox conjugates, such
as NPbare or NPVLA4 pep at equimolar particle concentrations
(results not shown).
Multifunctional nanoparticles induce DNA double-strand
breaks (DSB) and apoptosis in MM cells
It is well established that Dox induces DNA DSB and apoptosis of
cancer cells.
36 An early speciﬁc cellular response to DSBs in
mammalian cells is the phosphorylation of the histone protein
H2AX (g-H2AX), with respective foci formation.
37 Western blot and
immunocytochemical analysis showed that both free Dox and
NPDox/VLA4 pep induced H2AX phosphorylation and foci formation
in NCI-H929 cells (Figures 5a and b). Furthermore, both agents
induced apoptosis as was detected by ﬂow cytometric analysis of
the early apoptotic marker Annexin V (Figure 5c), and western
blot analysis of PARP and caspase-8 activation (Figure 5d). No
signiﬁcant caspase-9 activation was detected by either agent.
Altogether, these results suggest that free Dox and NPDox/VLA4 pep
exert their cytotoxic effects through similar cytotoxic mechanisms.
It is noteworthy that no cell death or caspase activation was
detected before 36h at these doses; therefore, DSB formation was
not a secondary event of apoptosis.
Multifunctional nanoparticles inhibit adhesion of MM cells to
ﬁbronectin and overcome CAM-DR
VLA4-pep serves two major purposes in our nanoparticle design:
(i) selective targeting of VLA-4-expressing MM cells and (ii)
inhibition of MM cell adhesion to the stroma to overcome
Figure 3. Cellular uptake studies. (a) Rhodamine-labeled nanoparticles with varying valency of VLA4-pep conjugates (n¼0--40/nanoparticle)
were prepared and incubated with NCI-H929 cells at 371C for the indicated time points. N¼20 peptide conjugates per nanoparticle triggered
the most efﬁcient uptake as determined by ﬂow cytometry. (b) In a separate experiment, control experiments with NPns, and competition
experiment with excess free VLA4-pep (2mM) was performed to determine receptor-mediated speciﬁcity of nanoparticle uptake.
Data represent means (±s.d.) of triplicate experiments. (c) Internalization of VLA-4-targeting nanoparticles was conﬁrmed with a Nikon A1R
confocal microscope using a  40 oil lens. Image acquisition was performed by Nikon Elements Ar software.
Figure 4. NPDox/VLA4 pep induces cytotoxicity against MM cells.
NCI-H929 MM cells were cultured in the presence of equivalent Dox
concentrations of NPDox/VLA4 pep(’), NPDox (m), or free Dox (K)f o r
48 and 72h. In all cases, cell viability was assessed by cell counting
kit-8 (CCK-8), and data represent means (±s.d.) of triplicate cultures.
Control experiments performed with NPDox/ns showed similar results
to NPDox.N P bare and NPVLA4 pep did not show any cytotoxic effects
at the concentrations tested (results not shown).
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we evaluated its efﬁciency in inhibiting MM cells adhesion
to ﬁbronectin. NPVLA4 pep inhibited adhesion of NCI-H929 cells
to ﬁbronectin in a dose-dependent manner (Figure 6a). Dox was
not incorporated into the nanoparticles for this assay to eliminate
compounding effects that would result from cell death. No
inhibition of adhesion was observed with NPbare or NPns (results
not shown). Next, we compared the cytotoxic effects of free Dox
or NPDox/VLA4 pep against MM cells in the presence or absence of
ﬁbronectin. Fibronectin-coated plates were used to allow for
adhesion of NCI-H929 cells, and BSA-coated plates were used
for culturing cells in suspension (MM cells do not adhere to
BSA-coated plates). Cells were then incubated with increasing
concentrations of NPDox/VLA4 pep or equivalent concentrations of
free Dox. Adhesion of NCI-H929 cells to ﬁbronectin caused CAM-
DR in the free Dox treatment group with a three fold IC50 shift
from 0.13±0.04 to 0.42±0.09mM (Figure 6b, left). In the NPDox/
VLA4 pep treatment group, however, the IC50 values merged
towards B0.2mM both for the adherent and suspension MM cells,
indicating that NPDox/VLA4 pep overcame CAM-DR (Figure 6b,
right). The signiﬁcance of these ﬁndings is best illustrated in
Figure 6c. When MM cells were cultured in suspension, the efﬁcacy
of free Dox in cell killing was similar to that of NPDox/VLA4 pep with
an IC50B0.13mM (Figure 6c, left). On the other hand, when
the cells were cultured in the presence of ﬁbronectin,
NPDox/VLA4 pep (IC50¼0.15±0.04mM) was more efﬁcacious
than free Dox (IC50¼0.42±0.09mM). These results suggest that
NPDox/VLA4 pep overcame CAM-DR in MM cells.
Multifunctional nanoparticles preferentially home to MM tumors
and inhibit tumor growth in vivo
To validate the therapeutic efﬁcacy of multifunctional nanoparti-
cles, SCID mice were injected with NCI-H929 tumors, and were
sorted into four treatment groups: (i) free Dox, (ii) NPDox/VLA4 pep,
(iii) NPDox and (iv) PBS (control). A pilot study performed to
determine the maximum tolerated dose of nanoparticles revealed
that 6mg/kg Dox equivalent NPDox/VLA4 pep, injected intrave-
nously on days 1, 3 and 5, resulted in p15% weight loss during a
2-week period (results not shown). This dose was therefore taken
as the maximum tolerated dose for nanoparticles and was used in
the in vivo study. When the tumors were palpable, each mouse
was injected with 6mg/kg Dox equivalent nanoparticles, or free
Dox on days 1, 3 and 5. Both free Dox and NPDox/VLA4 pep resulted
in dramatic tumor growth inhibition (Figure 7a). However, at the
dose used, mice in the free Dox group lost a signiﬁcant amount of
body weight by day 7 (415%), and demonstrated moribundity.
Therefore, all animals in the free Dox group were killed on day 7 as
a result of signiﬁcant systemic toxicity (Figure 7b). On the other
hand, the NPDox/VLA4 pep group only lost B10% body weight
during the 2-week study period (Figure 7b). These results indicate
that NPDox/VLA4 pep has a much-improved therapeutic index
when compared with free Dox. NPDox also showed tumor growth
inhibition, however, it was signiﬁcantly less efﬁcacious than
NPDox/VLA4 pep (Figure 7a, right). Ex-vivo mechanistic studies
performed on tumors dissected on day 5 showed that all drug
treatment groups induced apoptosis associated with caspase-3
activation (Figure 7c).
NPDox/VLA4 pep can expectedly accumulate in the tumor
through the VLA-4 targeting functionality as well as the enhanced
permeation and retention effect, resulting in reduced systemic
toxicity. To evaluate enhanced tumor accumulation, we studied
the tissue biodistribution of Dox for all treatment groups. Mice
were injected with 10mg/kg Dox, and tissues were dissected 24h
after drug administration for analysis by ﬂuorescence spectro-
scopy. No signiﬁcant difference was detected in the distribution of
Dox in lung, kidney, heart, or spleen at 24h, however, signiﬁcantly
more Dox accumulated in the tumor for the NPDox/VLA4 pep group
when compared with free Dox and NPDox, reaching to B10 and
B5 fold higher levels, respectively (Figure 7d). These results
are consistent with the enhanced inhibition of tumor growth we
observed with NPDox/VLA4 pep and demonstrate that incorporating
VLA4-pep to the nanoparticles enabled enhanced targeting of
VLA-4 expressing MM tumors.
Figure 5. NPDox/VLA4 pep induces DNA DSBs and apoptosis in MM cells. NCI-H929 cells were treated with 250nM Dox equivalents of NPDox/
VLA4 pep or free Dox for 0--48h. (a) Phosphorylation of DNA damage response protein H2AX at Ser
139 was assayed by western blotting.
(b) Respective H2AX foci formation was assayed by immunocytochemistry (right). Representative images are shown. Apoptosis was
assessed by ﬂow cytometry following Annexin V-FITC staining (c), and by western blotting for PARP cleavage, and caspase-8 and caspase-9
activation (d). For ﬂow cytometric analysis, data represent means (±s.d.) of triplicate experiments. For western blotting, representative images
are shown.
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performed on three additional mice from each group on day 5.
Systemic toxicity was detectable in all treatment groups as evident
from white blood cell, red blood cell and thrombocyte
counts (Figure 7e). The NPDox/VLA4 pep group, however, showed
signiﬁcantly less toxicity on white blood cell and thrombocytes
when compared with free Dox (Figure 7e).
Dox has been associated with clinically signiﬁcant cardiac and
renal toxicity.
38--40 We, therefore, evaluated the effect of the
nanoparticles on cardiac and renal weight loss. All drug treatment
groups showed only a mild reduction in cardiac mass. There
were no detectable difference between NPDox/VLA4 pep and free
Dox (Figure 7f), presumably because of the early time point (day 5)
the analysis was performed. On the other hand, we detected a
signiﬁcant difference in kidney weights as NPDox/VLA4 pep was
signiﬁcantly less toxic than free Dox, and did not cause any
signiﬁcant renal mass loss (Figure 7f). It is noteworthy that,
based on biodistribution studies, signiﬁcant Dox accumulation
was evident in kidneys in all treatment groups (Figure 7d). It is
possible that the reduced toxicity of the nanoparticles on kidneys
is because of the acid-sensitive hydrazone bond, which releases
active Dox only after receptor-mediated uptake, or in the acidic
microenvironment of the tumor tissue.
Nanoparticles are known to accumulate in and be cleared
by the reticuloendothelial system organs (spleen/liver).
14,41 We,
therefore, analyzed the effect of nanoparticles on the spleen and
liver. All drug treatment groups showed signiﬁcant accumulation
and severe mass loss in spleen, with no detectable difference
between nanoparticles and free Dox (Figure 7f). Histopathological
examination revealed severe hypoplasia of both erthroid and
myeloid elements in all drug treatment groups. Nanoparticles,
however, showed only moderate ﬁbrosis, whereas severe ﬁbrosis
was evident in the free Dox group (Supplementary Figure 1A).
An increased accumulation of nanoparticles in the liver was
observed (Figure 7d), however, this was not associated with
increased mass loss. To the contrary, NPDox/VLA4 pep resulted in
signiﬁcantly less weight loss in liver when compared with free Dox
(Figure 7f). Increased accumulation in liver without increased
toxicity was also shown in previous studies
42,43 and could be due
to the acid-sensitive hydrazone bond, which requires an acidic
environment to release active Dox. Histopathological analysis
revealed moderate hepatocellular hypertrophy and degeneration
in free Dox group, whereas only mild effects were observed in
the nanoparticle treatment groups (Supplementary Figure 1B).
Altogether, these results indicate that NPDox/VLA4 pep showed
decreased overall systemic toxicity than free Dox.
Combined, our results suggest improved therapeutic index
for NPDox/VLA4 pep with dramatic tumor growth inhibition,
signiﬁcantly increased accumulation in tumor, and overall
decreased systemic toxicity when compared with free Dox.
DISCUSSION
In this study, we engineered multifunctional micellar nanoparticles
that target VLA-4 expressing MM cells selectively, while combining
adhesion-inhibitory and cytotoxic effects in a temporal fashion to
overcome CAM-DR. In our design, we used peptides as targeting
agents, which have several advantages over antibodies such as
favorable pharmacokinetics, facile derivatizing and manufacturing,
and lower cost.
44 In physiological systems, multiple low-afﬁnity
interactions are used to distinguish one cell type from another
and to provide selectivity.
45,46 We, therefore, selected a low-
afﬁnity VLA-4 antagonistic peptide (KdB0.25mM; Figure 1c), and
used micellar nanoparticles as dynamic self-assembling scaffolds
to multivalently present this peptide to target VLA-4 over-
expressing MM cells. Receptor-mediated endocytosis is a particu-
larly important aspect in our nanoparticle design, as the acidic
environment of the endocytic vesicles is required for active Dox
release (Figure 2e). Our results demonstrated that binding of
the nanoparticles to VLA-4 triggered receptor-mediated uptake
with an optimal valency of 20 peptides per micelle. Although the
optimal peptide valency may vary based on the peptide’s
monovalent afﬁnity, as well as its kon and koff rate constants,
these studies validated VLA-4 as a suitable target for targeted
drug delivery in MM.
One of the key ﬁndings of our study was that when MM cells
were allowed to adhere to the extracellular matrix protein
ﬁbronectin, NPDox/VLA4 pep proved to be more efﬁcacious than
free Dox, and signiﬁcantly overcame CAM-DR (Figure 6). These
results establish the signiﬁcance of targeting MM cells as well as
their interactions with the microenvironment in the design of
more effective novel therapeutics.
Several different mouse models of MM are described.
47 Here,
we used a subcutaneous xenograft model of MM for various
advantages this model provides, such as the formation of palpable
tumors, which makes tumor growth inhibition and biodistribution
studies feasible. Our results demonstrated that NPDox/VLA4 pep
preferentially accumulated in the tumor when compared with
free Dox and NPDox. Most importantly, NPDox/VLA4 pep showed
dramatic tumor growth inhibition with decreased overall
systemic toxicity, demonstrating improved therapeutic index.
It is noteworthy that VLA4-pep targets human VLA-4, and that
NPDox/VLA4 pep may have a different toxicity proﬁle in humans.
Figure 6. NPDox/VLA4 pep inhibits adhesion of MM cells to ﬁbronectin
and overcomes CAM-DR. (a) Calcein-labeled NCI-H929 MM cells
were allowed to adhere to ﬁbronectin-coated plates alone, or with
increasing concentrations of NPVLA4 pep. Nonadherent cells were
removed by washing with PBS, and adherent cells were quantitated
in a ﬂuorescence multi-well plate reader. Data represents means
(±s.d.) of triplicate experiments. *Po0.05, **Po0.01 when com-
pared with control. (b) NCI-H929 cells were allowed to adhere to
ﬁbronectin- or BSA-coated plates for 1h, and then treated with
equivalent Dox concentrations of NPDox/VLA4 pep, or free Dox for
72h. Cell viability was assessed by cell counting kit-8 (CCK-8), and
data represent means (± s.d.) of triplicate cultures. (c) An alternate
illustration of data presented in (b).
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growth of tumors in the absence of the BM microenvironment.
Therefore, the growth and survival advantages provided by the
microenvironment, and CAM-DR are not well recapitulated in
this model. As a result, the improvement of efﬁcacy observed with
NPDox/VLA4 pep using this model is at best an underestimate.
Figure 7. In vivo characterization of NPDox/VLA4 pep in a xenograft model of MM. Tumor bearing SCID mice were injected, intravenously, with
free Dox, NPDox/VLA4 pep,o rN P Dox at a dose of 6mg/kg Dox equivalents on days 1, 3 and 5. (a) Tumor growth inhibition was detected by
caliper measurements. All mice in free Dox group were killed on day 7 because of high systemic toxicity (weight loss 415%). NPDox/VLA4 pep,
was signiﬁcantly more efﬁcacious than NPDox with *Po0.05. Data shown are means (±s.e.) of n¼6--8 per treatment group. (b) Percentage of
body weight of the animals as a measure of systemic toxicity. Free Dox group dramatically lost weight (415%) and demonstrated
moribundity by day 7. Therefore, mice in this group were killed on day 7. Only B10% weight loss was observed with NPDox/VLA4 pep or NPDox
during the 2-week study period. (c) Ex-vivo mechanistic analysis of tumors for apoptosis. Three additional mice from each group were
dissected on day 5 and tumors were stained for activated caspase-3. Representative images of tumor cross-sections that were captured using
a Nikon Eclipse TS100 microscope at  20 magniﬁcation are shown. (d) Tissue biodistribution of Dox following treatment. Three mice from
each group were treated, intravenously, with 10mg/kg of Dox equivalent drugs. Mice were killed 24h after treatment and tissues were
analyzed for Dox accumulation. Data shown are means (±s.e.). *Po0.05, **Po0.01 when compared with free Dox group. (e, f) Complete
blood count and organ weights as a measure of systemic toxicity. Three additional mice from each group were dissected on day 5, and
complete blood count (white blood cell, red blood cell and thrombocyte) was performed. (e) Weights of excised heart, kidney, spleen and liver
are shown. (f) Data represent means (±s.e.). *Po0.05, when compared with free Dox group.
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NPDox/VLA4 pep in a BM model of MM such as the diffuse MM
model.
47
In summary, we have harnessed nanotechnology to develop a
combinational therapy approach for MM, where Dox-conjugated
nanoparticles selectively targeted VLA-4 expressing MM
cells, prevented development of CAM-DR, and dramatically
inhibited tumor growth with overall reduced systemic toxicity.
Taken together, this study provides the preclinical rationale for
the clinical evaluation of VLA-4 targeting, Dox-conjugated
multifunctional nanoparticles to improve patient outcome.
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